Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Im Fokus Onkologie
Erschienen in: Im Fokus Onkologie 7-8/2018

10.07.2018 | Mammakarzinom | Gynäkoonkologie

Update der S3-Leitlinie

Aktuelle Therapiestrategien beim primären Mammakarzinom

verfasst von: Dr. med. Jasmin Festl, Prof. Dr. med. Achim Wöckel

Erschienen in: Im Fokus Onkologie | Ausgabe 7-8/2018

Einloggen, um Zugang zu erhalten

Zusammenfassung

In der aktualisierten S3-Leitlinie für die Früherkennung, Diagnostik, Therapie und Nachsorge des Mammakarzinoms von Dezember 2017 haben sich auch Neuerungen für die Behandlung des frühen Brustkrebs’ ergeben. So hat sich vor allem im Hinblick auf das operative Vorgehen die Radikalität verringert. Die erweiterten Möglichkeiten der Bestrahlung und systemischen Therapie in der adjuvanten Situation sind ebenfalls in die neuen Empfehlungen eingegangen.
Literatur
1.
Robert-Koch-Institut. Gesellschaft der epidemiologischen Krebsregister in Deutschland e.V. (Hrsg). Krebs in Deutschland fur 2013/2014. 2017. 11. Ausg. Berlin, 2017.
2.
3.
Buchholz TA et al. Margins for breast-conserving surgery with wholebreast irradiation in stage I and II invasive breast cancer: American Society of Clinical Oncology endorsement of the Society of Surgical Oncology/American Society for Radiation Oncology consensus guideline. J Clin Oncol. 2014;32(14):1502–6.CrossRefPubMed
4.
Voogd AC et al. Differences in risk factors for local and distant recurrence after breast-conserving therapy or mastectomy for stage I and II breast cancer: pooled results of two large European randomized trials. J Clin Oncol. 2001;19(6):1688–97.CrossRefPubMed
5.
Fisher B, Anderson S. Conservative surgery for the management of invasive and noninvasive carcinoma of the breast: NSABP trials. National Surgical Adjuvant Breast and Bowel Project. World J Surg. 1994;18(1):63–9.CrossRefPubMed
6.
De La Cruz L et al. Overall Survival, Disease-Free Survival, Local Recurrence, and Nipple-Areolar Recurrence in the Setting of Nipple-Sparing Mastectomy: A Meta-Analysis and Systematic Review. Ann Surg Oncol. 2015;22(10):3241–9.CrossRef
7.
Piper M et al. Total skin-sparing mastectomy: a systematic review of oncologic outcomes and postoperative complications. Ann Plast Surg. 2013;70(4):435–7.CrossRefPubMed
8.
9.
Hoffmann J, Wallwiener D. Classifying breast cancer surgery: a novel, complexity-based system for oncological, oncoplastic and reconstructive procedures, and proof of principle by analysis of 1225 operations in 1166 patients. BMC Cancer. 2009;9:108.CrossRefPubMedPubMedCentral
10.
Andersson Y. et al. Axillary recurrence rate 5 years after negative sentinel node biopsy for breast cancer. Br J Surg. 2012;99(2):226–31.CrossRefPubMed
11.
Giuliano AE et al. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA. 2011;305(6):569–75.CrossRefPubMedPubMedCentral
12.
Giuliano AE et al. Locoregional Recurrence After Sentinel Lymph Node Dissection With or Without Axillary Dissection in Patients With Sentinel Lymph Node Metastases: Long-term Follow-up From the American College of Surgeons Oncology Group (Alliance) ACOSOG Z0011 Randomized Trial. Ann Surg. 2016;264(3):413–20.CrossRefPubMed
13.
Classe JM et al. Sentinel lymph node biopsy after neoadjuvant chemotherapy for advanced breast cancer: results of Ganglion Sentinelle et Chimiotherapie Neoadjuvante, a French prospective multicentric study. J Clin Oncol. 2009;27(5):726–32.CrossRefPubMed
14.
Boughey JC et al. Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial. JAMA. 2013;310(14):1455–61.CrossRefPubMedPubMedCentral
15.
Kuehn T et al. Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study. Lancet Oncol. 2013;14(7):609–18.CrossRefPubMed
16.
Trentin C et al. Predictors of invasive breast cancer and lymph node involvement in ductal carcinoma in situ initially diagnosed by vacuum-assisted breast biopsy: experience of 733 cases. Breast. 2012;21(5):635–40.CrossRefPubMed
17.
Chin-Lenn L et al. Predictors of treatment with mastectomy, use of sentinel lymph node biopsy and upstaging to invasive cancer in patients diagnosed with breast ductal carcinoma in situ (DCIS) on core biopsy. Ann Surg Oncol. 2014;21(1):66–73.CrossRefPubMed
18.
Virnig BA et al. Ductal carcinoma in situ of the breast: a systematic review of incidence, treatment, and outcomes. J Natl Cancer Inst. 2010;102(3):170–8.CrossRefPubMed
19.
Narod SA et al. Breast Cancer Mortality After a Diagnosis of Ductal Carcinoma In Situ. JAMA Oncol. 2015; 1(7):888–96.CrossRefPubMed
20.
Shamliyan T et al. Association between patient and tumor characteristics with clinical outcomes in women with ductal carcinoma in situ. J Natl Cancer Inst Monogr. 2010;2010(41):121–9.CrossRefPubMedPubMedCentral
21.
Marinovich ML et al. The Association of Surgical Margins and Local Recurrence in Women with Ductal Carcinoma In Situ Treated with Breast-Conserving Therapy: A Meta-Analysis. Ann Surg Oncol. 2016;23(12):3811–21.CrossRefPubMedPubMedCentral
22.
Rudloff U et al. The influence of margin width and volume of disease near margin on benefit of radiation therapy for women with DCIS treated with breast-conserving therapy. Ann Surg. 2010;251(4):583–91.CrossRefPubMed
23.
Lyman GH et al. Sentinel lymph node biopsy for patients with earlystage breast cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2014;32(13):1365–83.CrossRefPubMed
24.
Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet. 2011;378(9804):1707–16.CrossRef
25.
Haviland JS et al. The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials. Lancet Oncol. 2013;14(11):1086–94.CrossRefPubMed
26.
Whelan TJ et al. Long-term results of hypofractionated radiation therapy for breast cancer. N Engl J Med. 2010;362(6):513–20.CrossRefPubMed
27.
Bartelink H et al. Whole-breast irradiation with or without a boost for patients treated with breast-conserving surgery for early breast cancer: 20-year follow-up of a randomised phase 3 trial. Lancet Oncol. 2015;16(1):47–56.CrossRefPubMed
28.
Warnberg F et al. Effect of radiotherapy after breast-conserving surgery for ductal carcinoma in situ: 20 years follow-up in the randomized SweDCIS Trial. J Clin Oncol. 2014;32(32):3613–8.CrossRefPubMed
29.
Goodwin A et al. Post-operative radiotherapy for ductal carcinoma in situ of the breast. Cochrane Database Syst Rev. 2013;(11):CD000563.
30.
Goldhirsch A et al. Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer. Ann Oncol. 2011;22(8):1736–47.CrossRefPubMedPubMedCentral
31.
32.
Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365(9472):1687–717.CrossRef
33.
Sparano JA et al. Long-Term Follow-Up of the E1199 Phase III Trial Evaluating the Role of Taxane and Schedule in Operable Breast Cancer. J Clin Oncol. 2015;33(21):2353–60.CrossRefPubMedPubMedCentral
34.
Bria E et al. Benefit of taxanes as adjuvant chemotherapy for early breast cancer: pooled analysis of 15,500 patients. Cancer. 2006;106(11):2337–44.CrossRefPubMed
35.
Martin M et al. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer. J Natl Cancer Inst. 2008;100(11):805–14.CrossRefPubMed
36.
Moebus V et al. Intense dose-dense sequential chemotherapy with epirubicin, paclitaxel, and cyclophosphamide compared with conventionally scheduled chemotherapy in high-risk primary breast cancer: mature results of an AGO phase III study. J Clin Oncol. 2010;28(17):2874–80.CrossRefPubMed
37.
Jones S et al. Docetaxel With Cyclophosphamide Is Associated With an Overall Survival Benefit Compared With Doxorubicin and Cyclophosphamide: 7-Year Follow-Up of US Oncology Research Trial 9735. J Clin Oncol.2009;27(8):1177–83.CrossRefPubMed
38.
von Minckwitz G et al. Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neo-adjuvant chemotherapy trials. Breast Cancer Res Treat. 2011;125(1):145–56.CrossRef
39.
Cortazar P et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014;384(9938):164–72.CrossRefPubMed
40.
Romond EH et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005;353(16):1673–84.CrossRefPubMed
41.
Moja L et al. Trastuzumab containing regimens for early breast cancer. Cochrane Database Syst Rev. 2012;(4):CD006243.
42.
Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet. 2011;378(9793):771–84.CrossRef
43.
Colleoni M et al. Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2018;19(1):127–38.CrossRefPubMed
44.
Davies C et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet. 2013;381(9869):805–16.CrossRefPubMedPubMedCentral
45.
Burstein HJ et al. Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: american society of clinical oncology clinical practice guideline focused update. J Clin Oncol. 2014;32(21):2255–69.CrossRefPubMedPubMedCentral
46.
47.
Blok EJ et al. Optimal Duration of Extended Adjuvant Endocrine Therapy for Early Breast Cancer; Results of the IDEAL Trial (BOOG 2006-05). J Natl Cancer Inst. 2018;110(1).
Metadaten
Titel
Update der S3-Leitlinie
Aktuelle Therapiestrategien beim primären Mammakarzinom
verfasst von
Dr. med. Jasmin Festl
Prof. Dr. med. Achim Wöckel
Publikationsdatum
10.07.2018
Verlag
Springer Medizin
Erschienen in
Im Fokus Onkologie / Ausgabe 7-8/2018
Print ISSN: 1435-7402
Elektronische ISSN: 2192-5674
DOI
https://doi.org/10.1007/s15015-018-3605-y

Weitere Artikel der Ausgabe 7-8/2018

Im Fokus Onkologie 7-8/2018 Zur Ausgabe

Pneumoonkologie

Kasten 1: Was wird in der S3-Leitlinie empfohlen?

Industrieforum

Update zu TKI-Absetzstudien

Pneumoonkologie

Interview: „Die molekulare Testung steht ganz am Anfang“

Gastroonkologie

Neue Ansätze in der Therapie des metastasierten Pankreaskarzinoms

Hämatoonkologie

AlloHCT als Postremissions-Strategie bei triple-negativer AML

Industrieforum

Checkpointinhibition plus Chemotherapie beim NSCLC auf dem Prüfstand

Weitere Lesetipps

Systemtherapie des Prostatakarzinoms im hohen Alter

CME: Postneoadjuvante Therapie des Mammakarzinoms

ANZEIGE

Sichere Antikoagulation bei ständig wechselnden Risikokonstellationen

ANZEIGE

CAT: Was tun bei Lücken in der Evidenz

ANZEIGE

Herausforderungen und Management krebsassoziierter Thrombosen

Der "ideale Kandidat" für eine Salvage-Lymphadenektomie bei Prostatakarzinom

Weitere Lesetipps

ANZEIGE

Dexpanthenol verstärkt die positiven Effekte der LASH-Methode

Zeitdieben in der Praxis den Kampf ansagen

ANZEIGE

Im Dialog mit jungen Dermatologen: Wund- und Narbenversorgung in der Praxis

ANZEIGE

Erfolgreiche Therapie von hypertrophen Narben und Keloiden

Kein Abstrich bei chronischen Wunden ohne Entzündungszeichen!

Gezielt und dauerhaft gegen Akne

Bildnachweise